分组1 - Local Bounti Corporation reported a quarterly loss of $1.63 per share, better than the Zacks Consensus Estimate of a loss of $1.95, and improved from a loss of $3 per share a year ago, resulting in an earnings surprise of +16.41% [1] - The company posted revenues of $12.1 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 1.6%, but showing an increase from $9.44 million in the same quarter last year [2] - Local Bounti shares have increased approximately 21.3% since the beginning of the year, outperforming the S&P 500's gain of 9.6% [3] 分组2 - The earnings outlook for Local Bounti is mixed, with the current consensus EPS estimate for the coming quarter at -$1.44 on revenues of $13.9 million, and -$8.90 on revenues of $59.7 million for the current fiscal year [7] - The Agriculture - Operations industry, to which Local Bounti belongs, is currently ranked in the bottom 22% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Innoviz Technologies shares have added about 8.3% since the beginning of the year versus the S&P 500's gain of 9.6%. What's Next for Innoviz Technologies? While Innoviz Technologies has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectat ...

分组1 - Gladstone Investment (GAIN) reported quarterly earnings of $0.24 per share, exceeding the Zacks Consensus Estimate of $0.23 per share, with an earnings surprise of +4.35% [1] - The company posted revenues of $23.54 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 1.68%, compared to year-ago revenues of $22.18 million [2] - Over the last four quarters, Gladstone Investment has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] 分组2 - The stock has gained approximately 7.7% since the beginning of the year, while the S&P 500 has increased by 8.4% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the coming quarter is $0.23 on $24.35 million in revenues, and $0.89 on $97.14 million in revenues for the current fiscal year [7] 分组3 - The Zacks Industry Rank indicates that the Financial - SBIC & Commercial Industry is currently in the bottom 27% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that tracking these revisions can be beneficial for investors [5] - The estimate revisions trend for Gladstone Investment was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6]

Core Insights - Southland Holdings (SLND) reported a quarterly loss of $0.19 per share, better than the Zacks Consensus Estimate of a loss of $0.28, and an improvement from a loss of $0.96 per share a year ago, resulting in an earnings surprise of +32.14% [1] - The company posted revenues of $215.38 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 9.08%, and down from $251.51 million year-over-year [2] - Southland shares have increased by approximately 38.2% since the beginning of the year, outperforming the S&P 500's gain of 8.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.21 on revenues of $247.7 million, and for the current fiscal year, it is -$0.68 on revenues of $972.9 million [7] - The estimate revisions trend for Southland was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Building Products - Miscellaneous industry, to which Southland belongs, is currently in the top 41% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Metagenomi shares have lost about 49.3% since the beginning of the year versus the S&P 500's gain of 8.4%. What's Next for Metagenomi? While Metagenomi has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s) ...

Company Performance - WideOpenWest reported a quarterly loss of $0.22 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.15, and compared to a loss of $0.13 per share a year ago, indicating an earnings surprise of -46.67% [1] - The company posted revenues of $144.2 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.14%, but down from $158.8 million in the same quarter last year [2] - Over the last four quarters, WideOpenWest has surpassed consensus EPS estimates only once, while it has topped consensus revenue estimates three times [2] Stock Performance - WideOpenWest shares have declined approximately 35.7% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.20 on revenues of $141.3 million, and for the current fiscal year, it is -$0.78 on revenues of $574.9 million [7] Industry Outlook - The Cable Television industry, to which WideOpenWest belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, suggesting a challenging environment for the company [8] - The performance of WideOpenWest's stock may be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Core Viewpoint - MidCap Financial Investment (MFIC) reported quarterly earnings of $0.39 per share, exceeding the Zacks Consensus Estimate of $0.37 per share, but down from $0.45 per share a year ago, indicating a mixed performance in earnings despite a positive surprise this quarter [1][2]. Financial Performance - The company posted revenues of $81.25 million for the quarter ended June 2025, which missed the Zacks Consensus Estimate by 0.5% and represents an increase from $69.16 million year-over-year [2]. - Over the last four quarters, MidCap Financial has surpassed consensus EPS estimates two times, but has not beaten consensus revenue estimates during the same period [2]. Stock Performance - MidCap Financial shares have declined approximately 6.7% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3]. - The current consensus EPS estimate for the upcoming quarter is $0.38 on revenues of $82.39 million, and for the current fiscal year, it is $1.50 on revenues of $325.08 million [7]. Industry Outlook - The Financial - Miscellaneous Services industry, to which MidCap Financial belongs, is currently ranked in the top 25% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]. - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact MidCap Financial's stock performance [5].

Core Viewpoint - Agenus reported a quarterly loss of $1 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.78, but an improvement from a loss of $2.52 per share a year ago [1] Financial Performance - The company posted revenues of $25.7 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 2.68% and showing an increase from $23.51 million in the same quarter last year [2] - Over the last four quarters, Agenus has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Agenus shares have increased approximately 75.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.6% [3] Future Outlook - The company's earnings outlook will be crucial for determining the sustainability of its stock price movement, with current consensus EPS estimate for the coming quarter at -$0.20 on revenues of $24.97 million, and for the current fiscal year at $1.56 on revenues of $246.08 million [7] - The estimate revisions trend for Agenus was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Agenus belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Company Performance - Enanta Pharmaceuticals reported a quarterly loss of $0.85 per share, which was better than the Zacks Consensus Estimate of a loss of $1.25, representing an earnings surprise of +32.00% [1] - The company posted revenues of $18.31 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 21.29% and showing an increase from $17.97 million in the same quarter last year [2] - Over the last four quarters, Enanta has surpassed consensus EPS estimates two times and topped revenue estimates twice [2] Stock Movement and Outlook - Enanta Pharmaceuticals shares have increased by approximately 20% since the beginning of the year, outperforming the S&P 500's gain of 8.6% [3] - The future performance of the stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is -$1.21 on revenues of $15.35 million, and for the current fiscal year, it is -$4.33 on revenues of $62.35 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Enanta belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Enanta's stock may also be influenced by the overall outlook for the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Core Viewpoint - Core Scientific, Inc. reported a quarterly loss of $0.04 per share, outperforming the Zacks Consensus Estimate of a loss of $0.07, indicating a positive earnings surprise of +42.86% [1] - The company generated revenues of $78.63 million for the quarter ended June 2025, which was 2.28% below the Zacks Consensus Estimate and a significant decrease from $141.1 million in the same quarter last year [2] Financial Performance - Over the last four quarters, Core Scientific has exceeded consensus EPS estimates three times and topped revenue estimates twice [2] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $111.86 million, while for the current fiscal year, the estimate is $1.44 on revenues of $412.08 million [7] Market Position - Core Scientific shares have increased by approximately 2.1% since the beginning of the year, underperforming compared to the S&P 500's gain of 7.8% [3] - The company currently holds a Zacks Rank of 3 (Hold), suggesting that its shares are expected to perform in line with the market in the near future [6] Industry Outlook - The Financial - Miscellaneous Services industry, to which Core Scientific belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Core Scientific's stock performance [5]